Cargando…
Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes
The balance between neurodegeneration, neuroinflammation, neuroprotection, and COVID-19-directed therapy may underly the heterogeneity of SARS-CoV-2′s neurological outcomes. A total of 105 patients hospitalized with a diagnosis of COVID-19 had serum collected over a 6 month period to assess neuroinf...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698659/ https://www.ncbi.nlm.nih.gov/pubmed/34944606 http://dx.doi.org/10.3390/biomedicines9121791 |
_version_ | 1784620330010017792 |
---|---|
author | Laudanski, Krzysztof Hajj, Jihane Restrepo, Mariana Siddiq, Kumal Okeke, Tony Rader, Daniel J. |
author_facet | Laudanski, Krzysztof Hajj, Jihane Restrepo, Mariana Siddiq, Kumal Okeke, Tony Rader, Daniel J. |
author_sort | Laudanski, Krzysztof |
collection | PubMed |
description | The balance between neurodegeneration, neuroinflammation, neuroprotection, and COVID-19-directed therapy may underly the heterogeneity of SARS-CoV-2′s neurological outcomes. A total of 105 patients hospitalized with a diagnosis of COVID-19 had serum collected over a 6 month period to assess neuroinflammatory (MIF, CCL23, MCP-1), neuro-injury (NFL, NCAM-1), neurodegenerative (KLK6, τ, phospho τ, amyloids, TDP43, YKL40), and neuroprotective (clusterin, fetuin, TREM-2) proteins. These were compared to markers of nonspecific inflammatory responses (IL-6, D-dimer, CRP) and of the overall viral burden (spike protein). Data regarding treatment (steroids, convalescent plasma, remdasavir), pre-existing conditions, and incidences of strokes were collected. Amyloid β42, TDP43, NF-L, and KLK6 serum levels declined 2–3 days post-admission, yet recovered to admission baseline levels by 7 days. YKL-40 and NCAM-1 levels remained elevated over time, with clusters of differential responses identified among TREM-2, TDP43, and YKL40. Fetuin was elevated after the onset of COVID-19 while TREM-2 initially declined before significantly increasing over time. MIF serum level was increased 3–7 days after admission. Ferritin correlated with TDP-43 and KLK6. No treatment with remdesivir coincided with elevations in Amyloid-β40. A lack of convalescent plasma resulted in increased NCAM-1 and total tau, and steroidal treatments did not significantly affect any markers. A total of 11 incidences of stroke were registered up to six months after initial admission for COVID-19. Elevated D-dimer, platelet counts, IL-6, and leukopenia were observed. Variable MIF serum levels differentiated patients with CVA from those who did not have a stroke during the acute phase of COVID-19. This study demonstrated concomitant and opposite changes in neurodegenerative and neuroprotective markers persisting well into recovery. |
format | Online Article Text |
id | pubmed-8698659 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86986592021-12-24 Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes Laudanski, Krzysztof Hajj, Jihane Restrepo, Mariana Siddiq, Kumal Okeke, Tony Rader, Daniel J. Biomedicines Article The balance between neurodegeneration, neuroinflammation, neuroprotection, and COVID-19-directed therapy may underly the heterogeneity of SARS-CoV-2′s neurological outcomes. A total of 105 patients hospitalized with a diagnosis of COVID-19 had serum collected over a 6 month period to assess neuroinflammatory (MIF, CCL23, MCP-1), neuro-injury (NFL, NCAM-1), neurodegenerative (KLK6, τ, phospho τ, amyloids, TDP43, YKL40), and neuroprotective (clusterin, fetuin, TREM-2) proteins. These were compared to markers of nonspecific inflammatory responses (IL-6, D-dimer, CRP) and of the overall viral burden (spike protein). Data regarding treatment (steroids, convalescent plasma, remdasavir), pre-existing conditions, and incidences of strokes were collected. Amyloid β42, TDP43, NF-L, and KLK6 serum levels declined 2–3 days post-admission, yet recovered to admission baseline levels by 7 days. YKL-40 and NCAM-1 levels remained elevated over time, with clusters of differential responses identified among TREM-2, TDP43, and YKL40. Fetuin was elevated after the onset of COVID-19 while TREM-2 initially declined before significantly increasing over time. MIF serum level was increased 3–7 days after admission. Ferritin correlated with TDP-43 and KLK6. No treatment with remdesivir coincided with elevations in Amyloid-β40. A lack of convalescent plasma resulted in increased NCAM-1 and total tau, and steroidal treatments did not significantly affect any markers. A total of 11 incidences of stroke were registered up to six months after initial admission for COVID-19. Elevated D-dimer, platelet counts, IL-6, and leukopenia were observed. Variable MIF serum levels differentiated patients with CVA from those who did not have a stroke during the acute phase of COVID-19. This study demonstrated concomitant and opposite changes in neurodegenerative and neuroprotective markers persisting well into recovery. MDPI 2021-11-29 /pmc/articles/PMC8698659/ /pubmed/34944606 http://dx.doi.org/10.3390/biomedicines9121791 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Laudanski, Krzysztof Hajj, Jihane Restrepo, Mariana Siddiq, Kumal Okeke, Tony Rader, Daniel J. Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes |
title | Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes |
title_full | Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes |
title_fullStr | Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes |
title_full_unstemmed | Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes |
title_short | Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes |
title_sort | dynamic changes in central and peripheral neuro-injury vs. neuroprotective serum markers in covid-19 are modulated by different types of anti-viral treatments but do not affect the incidence of late and early strokes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698659/ https://www.ncbi.nlm.nih.gov/pubmed/34944606 http://dx.doi.org/10.3390/biomedicines9121791 |
work_keys_str_mv | AT laudanskikrzysztof dynamicchangesincentralandperipheralneuroinjuryvsneuroprotectiveserummarkersincovid19aremodulatedbydifferenttypesofantiviraltreatmentsbutdonotaffecttheincidenceoflateandearlystrokes AT hajjjihane dynamicchangesincentralandperipheralneuroinjuryvsneuroprotectiveserummarkersincovid19aremodulatedbydifferenttypesofantiviraltreatmentsbutdonotaffecttheincidenceoflateandearlystrokes AT restrepomariana dynamicchangesincentralandperipheralneuroinjuryvsneuroprotectiveserummarkersincovid19aremodulatedbydifferenttypesofantiviraltreatmentsbutdonotaffecttheincidenceoflateandearlystrokes AT siddiqkumal dynamicchangesincentralandperipheralneuroinjuryvsneuroprotectiveserummarkersincovid19aremodulatedbydifferenttypesofantiviraltreatmentsbutdonotaffecttheincidenceoflateandearlystrokes AT okeketony dynamicchangesincentralandperipheralneuroinjuryvsneuroprotectiveserummarkersincovid19aremodulatedbydifferenttypesofantiviraltreatmentsbutdonotaffecttheincidenceoflateandearlystrokes AT raderdanielj dynamicchangesincentralandperipheralneuroinjuryvsneuroprotectiveserummarkersincovid19aremodulatedbydifferenttypesofantiviraltreatmentsbutdonotaffecttheincidenceoflateandearlystrokes |